NICE Stuns Merck With Demand For Additional Daxas Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE says it wants Merck to carry out an additional clinical trial of Daxas in conjunction with triple therapy for COPD, if the company is to get its drug into the NHS.
You may also be interested in...
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses
Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose
Bronchodilator is approved for COPD at a 75 mcg dose, compared to 150 mcg and 300 mcg in Europe. Label nods to quality-of-life data.
Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
The narrowed indication granted for Forest Laboratories Inc.'s newly approved chronic obstructive pulmonary disease drug Daliresp (roflumilast) means that a quarter of all diagnosed COPD patients, or three million people, will be eligible for treatment, the firm said.